Envestnet Asset Management Inc. Boosts Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Envestnet Asset Management Inc. increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 259,429 shares of the medical instruments supplier's stock after purchasing an additional 16,886 shares during the period. Envestnet Asset Management Inc. owned approximately 1.15% of LeMaitre Vascular worth $23,904,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in LeMaitre Vascular during the 4th quarter worth approximately $14,900,000. Segall Bryant & Hamill LLC acquired a new position in shares of LeMaitre Vascular during the 4th quarter valued at $5,446,000. JPMorgan Chase & Co. grew its stake in shares of LeMaitre Vascular by 45.9% in the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock valued at $13,590,000 after buying an additional 46,430 shares during the period. Barclays PLC increased its holdings in shares of LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after acquiring an additional 29,180 shares in the last quarter. Finally, State Street Corp raised its holdings in LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock worth $76,363,000 after buying an additional 28,525 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.79% of the company's stock.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of recent analyst reports. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Trading Up 1.0 %

Shares of NASDAQ:LMAT traded up $0.85 on Tuesday, reaching $84.63. 145,216 shares of the company traded hands, compared to its average volume of 159,602. The business's 50-day simple moving average is $88.88 and its 200 day simple moving average is $93.68. The stock has a market capitalization of $1.91 billion, a P/E ratio of 46.25, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52 week low of $62.39 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio (DPR) is 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.